Latest Profitability News

FlexiRoam Limited reported an 8.6% revenue decline for FY25 but achieved a remarkable turnaround in the second half, posting positive EBITDA and net profit after a CEO-led operational reset.

Hubify Limited reports a significant turnaround in FY25 with positive EBITDA and a robust cash position, despite a strategic revenue decline. The company’s focus on recurring managed services and cybersecurity positions it well for future growth.

3P Learning reported a 30% rise in underlying EBITDA to $15.5 million for FY25, alongside a return to statutory profitability and a key acquisition to strengthen its literacy offerings.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

Pure Foods Tasmania has executed a decisive operational and financial turnaround, cutting costs and strengthening its balance sheet, while targeting breakeven by mid-2026 with ambitious growth plans.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

PointsBet reports a 6% revenue increase and returns to normalised EBITDA profitability in FY25, while the board unanimously backs MIXI Australia’s all-cash $1.25 per share takeover offer, urging shareholders to reject a rival hostile bid.

Aerometrex reported a slight dip in overall revenue for FY25 but achieved record growth in its MetroMap subscription business, driving a 19.8% rise in EBITDA. Strategic shifts and new leadership position the company for a leaner, more profitable future.

Waypoint REIT reported steady distributable earnings for the first half of 2025 alongside a significant rise in statutory net profit, while extending debt facilities and launching a $50 million buyback program.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Harvey Norman Holdings Limited has announced a fully franked ordinary dividend of AUD 0.145 per share for the six months ending June 2025, signaling steady returns for shareholders.